Details for New Drug Application (NDA): 022524
✉ Email this page to a colleague
NDA 022524 describes ZUPLENZ, which is a drug marketed by Aquestive and is included in one NDA. There are two patents protecting this drug. Additional details are available on the ZUPLENZ profile page.
The generic ingredient in ZUPLENZ is ondansetron. There are twenty-eight drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the ondansetron profile page.
The generic ingredient in ZUPLENZ is ondansetron. There are twenty-eight drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the ondansetron profile page.
Summary for 022524
| Tradename: | ZUPLENZ |
| Applicant: | Aquestive |
| Ingredient: | ondansetron |
| Patents: | 2 |
Medical Subject Heading (MeSH) Categories for 022524
Profile for product number 001
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FILM;ORAL | Strength | 8MG | ||||
| Approval Date: | Jul 2, 2010 | TE: | RLD: | Yes | |||||
| Patent: | 8,580,830 | Patent Expiration: | Nov 23, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
